Enzyme linked immunosorbent assay: determination of anti-adenovirus antibodies in an infant population

Weinberg, Adriana; Fink, Maria Cristina Domingues da Silva; Takimoto, Sueko; Ishida, María Akíko; Souza, Maria Candida Oliveira De

doi:10.1590/s0036-46651989000500007

Cited by 11 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Weinberg et al 21 examined the prevalence of anti-adenovirus antibodies in 116 infants between 1 and 24 months old and showed that more than 80% of the children had been infected by adenoviruses by the age of 10 months. Rosenecker et al 22 in a noteworthy report demonstrated that IgG antibodies against adenovirus were present in 192 of 199 cystic fibrosis patients (96.5%), and were significantly higher in cystic fibrosis patients older than 7 years than in younger patients and in age matched controls.…”

Section: Discussionmentioning

confidence: 99%

Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver

et al. 1999

View full text Add to dashboard Cite

Although adenovirus is an attractive vehicle for transferring although intraportal infusion of adenoviruses carrying a therapeutic genes in vivo, animal studies have indicated reporter lacZ gene resulted in transient high levels of transthat the clinical usefulness of adenoviruses may be limited gene expression in the rat liver, intraportal readministration by their immunogenicity. Although immunosuppressive of adenoviruses failed to induce detectable levels of transstrategies around the time of initial exposure of adenogene expression. Conversely, when animals were treated viruses have been shown to prevent the formation of neutransiently with cyclophosphamide before the intraportal tralizing antibodies and permit the successful readminisreadministration of adenoviruses, development of neutration of adenoviruses in animals, the practicality of the tralizing antibodies and antigen-specific T cell proliferation approaches remains questionable. Because the majority of in response to adenoviral readministration was significantly prospective gene therapy patients have already been suppressed and successful re-expression of the transgene infected with wild-type adenoviruses, initial treatment with was achievable. These results may have important impliadenoviruses in humans may correspond to readminiscations for efficacy considerations when adenoviral vectors tration of adenoviruses into animals. It is shown here that are employed in clinical settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Doubtful or discrepant samples were restained and read at least twice to check for reproducibility. An indirect immunofluorescence test was done for adenovirus and respiratory syncytial virus for the detection of antibody response as described elsewere 31 .…”

Section: Methodsmentioning

confidence: 99%

Outbreak of influenza type A (H1N1) in Iporanga, São Paulo State, Brazil

Paiva

Ishida

Hanashiro

et al. 2001

Rev. Inst. Med. trop. S. Paulo

Self Cite

View full text Add to dashboard Cite

SUMMARYFrom June to July 1999 an outbreak of acute respiratory illness occurred in the town of Iporanga. Out of a total of 4,837 inhabitants, 324 cases were notified to the Regional Surveillance Service. Influenza virus was isolated from 57.1% of the collected samples and 100% seroconversion to influenza A (H1N1) was obtained in 20 paired sera tested. The isolates were related to the A/ Bayern/07/95 strain (H1N1). The percentages of cases notified during the outbreak were 28.4%, 29.0%, 20.7%, 6.2% and 15.7% in the age groups of 0-4, 5-9, 10-14, 15-19 and older than 20 years, respectively. The highest proportion of positives was observed among children younger than 14 years and no cases were notified in people older than 65 years, none of whom had been recently vaccinated against influenza. These findings suggest a significant vaccine protection against A/Bayern/7/95, the H1 component included in the 1997-98 influenza vaccine for elderly people. This viral strain is antigenically and genetically related to A/Beijing/ 262/95, the H1 component of the 1999 vaccine. Vaccines containing A/Beijing/262/95 (H1N1) stimulated post-immunization hemagglutination inhibition antibodies equivalent in frequency and titre to both A/Beijing/262/95-like and A/Bayern/7/95-like viruses. Thus, this investigation demonstrates the effectiveness of vaccination against influenza virus in the elderly.

show abstract

“…There have been promising attempts to modify the E4 region by either deleting the entire E4 or introducing alterations within individual E4 coding regions so as to minimize immunogenicity, eliminate the toxicity of adenoviral vectors and improve transgene persistence in vivo. 3,17,18,[27][28][29][30] In this study, we developed a recombinant adenovirus with deleted E1 and E3 regions and an inactivated E4 to minimize expression of viral proteins. We used this vector to express a human tumor suppressor gene p53.…”

Section: Introductionmentioning

confidence: 99%

Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement

Bouvet

Price

et al. 1999

Gene Ther

View full text Add to dashboard Cite

A recombinant adenovirus with deleted E1 and E3, and E4-mouse livers from days 3 to 28. Ten weeks after injection, inactivated by replacing the E4 promoter with a synthetic p53 gene expression was still detected in G4-treated promoter composed of a minimal TATA box and five con-C57BL/6 mice at similar levels, but was not detectable in sensus yeast GAL4-binding site elements was developed WT-treated mice. Vector-induced liver toxicity was evaluand used to express the human tumor suppresser gene ated by analyzing serum transaminases (SGOT and p53. The toxicity and immunogenicity of this vector and SGPT) activities. In all cases, SGOT and SGPT activities vector-mediated p53 gene expression in vivo were studied were markedly decreased in EG-treated C3H and C57BL/6 in immunocompetent C3H and C57BL/6 mice. Expression mice compared with those in EW-treated mice on days 3, of the late viral gene product, hexon protein, was observed 7 and 14 after injection. In C57BL/6 mice, the total antiin C3H and C57BL/6 mice injected with E4 wild-type adenoviral CTL activities were two-to three-fold higher in adenovirus constructs Adv-cmv-␤-Gal (BG), Adv-cmv-hp53 animals treated with EW vector than in those treated with (WT), and empty E1 − vector Adv-E4 (EW) 3 to 28 days EG vector. These results suggest that inactivation of the after injection, but was undetectable in mice treated with E4 promoter efficiently diminished the viral replication and E4 modified empty E1 − vector Adv-GAL4 (EG) or Adv-cmvthe late viral gene expression, reduced host immune hp53-GAL4 (G4). Expression of the p53 gene was response and consequently reduced toxicity and prolonged observed in both WT-and G4-injected C3H and C57BL/6 the duration of transgene expression in vivo.

show abstract

Enzyme linked immunosorbent assay: determination of anti-adenovirus antibodies in an infant population

Cited by 11 publications

References 10 publications

Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver

Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver

Outbreak of influenza type A (H1N1) in Iporanga, São Paulo State, Brazil

Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement

Contact Info

Product

Resources

About